Company news

Senseonics Holdings, Inc. news in 2022

Senseonics Holdings, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Senseonics Holdings, Inc. Reports Third Quarter 2022 Financial Results

November 7, 2022

Senseonics and Ascensia Announce a Collaboration with the Nurse Practitioner Group Designed to Expand Patient Access by Providing In-Office and At-Home Insertion Options for Eversense® E3 Continuous Glucose Monitoring System (CGM)

November 2, 2022

Senseonics Holdings, Inc. Schedules Third Quarter 2022 Earnings Release and Conference Call for November 8, 2022, at 4: 30 p.m. Eastern Time

October 24, 2022

Senseonics Announces CFO Transition

August 31, 2022

Senseonics Holdings, Inc. Reports Second Quarter 2022 Financial Results

August 8, 2022

Senseonics Announces a Positive Coverage Decision for Eversense® E3 CGM from Anthem

August 2, 2022

Senseonics Holdings, Inc. Schedules Second Quarter 2022 Earnings Release and Conference Call for August 9, 2022, at 4: 30 p.m. Eastern Time

July 25, 2022

Senseonics Announces CE Mark Approval of the Eversense E3 Continuous Glucose Monitoring System

June 15, 2022

Senseonics Holdings, Inc. Reports First Quarter 2022 Financial Results

May 9, 2022

Senseonics Holdings, Inc. Schedules First Quarter 2022 Earnings Release and Conference Call for May 10, 2022, at 4: 30 p.m. Eastern Time

April 25, 2022

Senseonics Announces the First Patient Implant of the Eversense E3 CGM System in the U.S.

April 5, 2022

Senseonics Announces Equity Grants to Employees Under Inducement Plan

March 31, 2022

Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results

February 28, 2022

Senseonics Holdings, Inc. Schedules Fourth Quarter and Full Year 2021 Earnings Release and Conference Call for March 1, 2022, at 4: 30 p.m. Eastern Time

February 14, 2022

Ascensia Diabetes Care announces FDA approval of the Eversense E3 continuous glucose monitoring system for use for up to 6 months

February 13, 2022

Senseonics Announces FDA Approval of the Eversense® E3 Continuous Glucose Monitoring System for Use for Up to 6 months; Provides 2022 Business Outlook

February 10, 2022

Senseonics Announces Business Updates

January 3, 2022

Calls in 2022

Decks in 2022